0001209191-23-037968.txt : 20230616 0001209191-23-037968.hdr.sgml : 20230616 20230616170514 ACCESSION NUMBER: 0001209191-23-037968 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230614 FILED AS OF DATE: 20230616 DATE AS OF CHANGE: 20230616 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hineline Lawrence J. CENTRAL INDEX KEY: 0001585697 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36274 FILM NUMBER: 231022152 MAIL ADDRESS: STREET 1: C/O INTRA-CELLULAR THERAPIES, INC. STREET 2: 3960 BROADWAY CITY: NEW YORK STATE: NY ZIP: 10032 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc. CENTRAL INDEX KEY: 0001567514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 364742850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 212-923-3344 MAIL ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: Oneida Resources Corp. DATE OF NAME CHANGE: 20130122 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-14 0 0001567514 Intra-Cellular Therapies, Inc. ITCI 0001585697 Hineline Lawrence J. C/O INTRA-CELLULAR THERAPIES, INC. 430 EAST 29TH STREET NEW YORK NY 10016 0 1 0 0 SVP of Finance CFO 1 Common Stock 2023-06-14 4 M 0 40472 53.63 A 40472 D Common Stock 2023-06-14 4 M 0 25082 23.94 A 65554 D Common Stock 2023-06-14 4 M 0 11762 36.89 A 77316 D Common Stock 2023-06-14 4 M 0 4538 56.73 A 81854 D Common Stock 2023-06-14 4 S 0 34227 63.35 D 47627 D Common Stock 2023-06-14 4 S 0 44035 64.37 D 3592 D Common Stock 2023-06-14 4 S 0 3592 65.01 D 0 D Stock Option (right to purchase) 53.63 2023-06-14 4 M 0 40472 0.00 D 2026-01-03 Common Stock 40472 0 D Stock Option (right to purchase) 23.94 2023-06-14 4 M 0 25082 0.00 D 2030-02-17 Common Stock 25082 0 D Stock Option (right to purchase) 36.89 2023-06-14 4 M 0 11762 0.00 D 2031-02-22 Common Stock 11762 5882 D Stock Option (right to purchase) 56.73 2023-06-14 4 M 0 4538 0.00 D 2032-03-09 Common Stock 4538 9078 D This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.795 to $63.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.79 to $64.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.81 to $65.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. All shares underlying this option have vested. On February 23, 2021, the reporting person was granted options to purchase 17,644 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date. On March 10, 2022, the reporting person was granted options to purchase 13,616 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date. /s/ Lawrence J. Hineline 2023-06-16